IL10 and cancer: Further evaluation is warranted to elucidate the dose–effect relationship for the treatment suppression of IL10, TNF-α, and IL12p70 in monocytes, PMNs, and B cells under IgM stimulation as potential infections during the treatment for cancer patients.